Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | January 06, 2026 | January 08, 2026 |
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, Chief Medical Officer | April 11, 2019 | April 12, 2019 |
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director | September 30, 2026 | October 03, 2026 |
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Director | June 25, 2026 | June 29, 2026 |
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Director | June 15, 2026 | June 17, 2026 |
| Immunovant, Inc.IMVT · Entity 3632 | Chief Medical Officer | March 19, 2021 | March 31, 2021 |
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | Director | January 05, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.91 · Expires 2036-01-05 | Direct | 5,500 |
Reported balance
After 2026-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-06 · Grant · Acquired 5,500 · Balance 5,500 F1: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,000 |
Reported balance
After 2026-01-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-06 · Grant · Acquired 4,000 · Balance 4,000 F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Akebia Therapeutics, Inc.
Report date April 11, 2019 · Filed April 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,332 |
Reported balance
After 2019-04-11 transaction · row 1
1 source rowRow 1 · 2019-04-11 · Disposition to issuer · Disposed 4,409 · Balance 96,332 F1: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units.
Avalo Therapeutics, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.33 · Expires 2036-09-30 | Direct | 1,322 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 1,322 · Balance 1,322 F2: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. F1: The options were granted on September 30, 2026, and are 100% vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on September 30, 2026, and are 100% vested.
F2: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 26,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 26,000 · Balance 26,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
First Tracks Biotherapeutics, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,194 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Exercise / conversion · Acquired 7,330 · Balance 19,194 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Exercise / conversion · Disposed 6,030 · Balance 0 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-15 · Exercise / conversion · Disposed 1,300 · Balance 0 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3: The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3: The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date.
Immunovant, Inc.
Report date March 19, 2021 · Filed March 31, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 129,365 |
Last balance in matching sequence
After 2021-03-19 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-03-19 · Grant · Acquired 97,600 · Balance 117,600 F1: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Row 2 · 2021-03-19 · Grant · Acquired 11,765 · Balance 129,365 F1: Represents the number of shares underlying restricted stock units awards ("RSUs"). F3: The original Form 4, filed on March 23, 2021, is being amended by this Form 4 amendment solely to correct an administrative error related to the disclosure of the vesting schedule for 11,765 RSUs. These RSUs vest in their entirety six months after the date of grant on September 19, 2021, subject to the Reporting Person providing continuous service to the Issuer as of such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-03-19 | Direct | 342,300 |
Reported balance
After 2021-03-19 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2021-03-19 · Grant · Acquired 342,300 · Balance 342,300 F4: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares underlying restricted stock units awards ("RSUs").
F2: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
F3: The original Form 4, filed on March 23, 2021, is being amended by this Form 4 amendment solely to correct an administrative error related to the disclosure of the vesting schedule for 11,765 RSUs. These RSUs vest in their entirety six months after the date of grant on September 19, 2021, subject to the Reporting Person providing continuous service to the Issuer as of such date.
F4: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
SAB Biotherapeutics, Inc.
Report date January 05, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.74 · Expires 2036-01-05 | Direct | 240,000 |
Reported balance
After 2026-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-05 · Grant · Acquired 240,000 · Balance 240,000 F1: Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029. F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029.
F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ChemoCentryx, Inc.
Report date October 20, 2022 · Filed October 24, 2022
Section 16 reporting ended · disclosed 2022-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 1
1 source rowRow 1 · 2022-10-20 · Disposition to issuer · Disposed 35,863 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.83 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-20 · Disposition to issuer · Disposed 307 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.83 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-20 · Disposition to issuer · Disposed 14,393 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $19.00 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-20 · Disposition to issuer · Disposed 21,052 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $19.00 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-20 · Disposition to issuer · Disposed 23,948 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.06 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-20 · Disposition to issuer · Disposed 4,504 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.60 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-20 · Disposition to issuer · Disposed 12,287 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-20 · Disposition to issuer · Disposed 11,600 · Balance 0 F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised,
F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.
Provention Bio, Inc.
Report date April 27, 2023 · Filed April 27, 2023
Section 16 reporting ended · disclosed 2023-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.67 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-27 · Disposition to issuer · Disposed 66,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full.
F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 20, 2022 Filed Oct 24, 2022 19:13 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerStock Option · Derivative | 14,393 | Not disclosed Strike: $29.83 | Not disclosed |
DisclosureSEC source: 0000899243-22-034089 · doc4.xml · derivative · entry 3 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,393 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:13 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerStock Option · Derivative | 307 | Not disclosed Strike: $29.83 | Not disclosed |
DisclosureSEC source: 0000899243-22-034089 · doc4.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 307 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:13 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerCommon Stock | 35,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-034089 · doc4.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2 · price: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares. Read SEC document |
| May 20, 2022 Filed May 24, 2022 19:27 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionRestricted Stock Units · Derivative | 7,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-031743 · doc4.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3 · derivative.exercise_date: 100% of the restricted stock units vested on May 20, 2022. Vested shares will be delivered to the Reporting Person within thirty (30) days following vest date. F3 · derivative.expiration_date: 100% of the restricted stock units vested on May 20, 2022. Vested shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| May 20, 2022 Filed May 24, 2022 19:27 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 7,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031743 · doc4.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of restricted stock units awarded on May 20, 2021. Read SEC document |
| March 27, 2022 Filed Mar 29, 2022 19:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionRestricted Stock Units · Derivative | 5,251 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-021541 · doc4.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,251 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3 · derivative.exercise_date: The restricted stock units awarded on March 27, 2019, vest in three equal installments on March 27, 2020, March 27, 2021, and March 27, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F3 · derivative.expiration_date: The restricted stock units awarded on March 27, 2019, vest in three equal installments on March 27, 2020, March 27, 2021, and March 27, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| March 27, 2022 Filed Mar 29, 2022 19:50 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 5,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021541 · doc4.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of restricted stock units awarded on March 27, 2019. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 20:46 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy) · Derivative | 14,700 | Not disclosed Strike: $29.83 | Not disclosed |
DisclosureSEC source: 0001209191-22-012915 · doc4.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,700 Underlying: Common Stock · 14,700 shares Expires 2032-02-22 F4 · price: Not applicable. F3 · derivative.exercise_date: The option was granted on February 22, 2022, and 25% of the total number of shares of common stock subject to the option vests on January 1, 2023, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 20:46 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantRestricted Stock Units · Derivative | 11,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-012915 · doc4.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,600 Underlying: Common Stock · 11,600 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · derivative.exercise_date: The restricted stock units awarded on February 22, 2022, vests in four equal installments on January 1, 2023, January 1, 2024, January 1, 2025, and January 1, 2026, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F2 · derivative.expiration_date: The restricted stock units awarded on February 22, 2022, vests in four equal installments on January 1, 2023, January 1, 2024, January 1, 2025, and January 1, 2026, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 20:52 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy) · Derivative | 45,000 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0001209191-21-060003 · doc4.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-10-05 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on October 5, 2021, and 25% of the total number of shares of common stock subject to the option vests on October 5, 2022, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date. Read SEC document |
| May 21, 2021 Filed May 24, 2021 19:55 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionRestricted Stock Units · Derivative | 4,660 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-035542 · doc4.xml · derivative · entry 4 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F6 · derivative.exercise_date: 100% of the restricted stock units vested on May 21, 2021. Vested shares will be delivered to the Reporting Person within thirty (30) days following vest date. F6 · derivative.expiration_date: 100% of the restricted stock units vested on May 21, 2021. Vested shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| May 21, 2021 Filed May 24, 2021 19:55 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 4,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035542 · doc4.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of restricted stock units awarded on May 21, 2020. Read SEC document |
| May 20, 2021 Filed May 24, 2021 19:55 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy) · Derivative | 4,504 | Not disclosed Strike: $10.06 | Not disclosed |
DisclosureSEC source: 0001209191-21-035542 · doc4.xml · derivative · entry 3 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,504 Underlying: Common Stock · 4,504 shares Expires 2031-05-20 F5 · price: Not applicable. F4 · derivative.exercise_date: The option granted on May 20, 2021, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 19:55 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantRestricted Stock Units · Derivative | 7,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-035542 · doc4.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,726 Underlying: Common Stock · 7,726 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3 · derivative.exercise_date: The restricted stock units awarded on May 20, 2021, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F3 · derivative.expiration_date: The restricted stock units awarded on May 20, 2021, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| March 27, 2021 Filed Mar 30, 2021 20:45 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionRestricted Stock Units · Derivative | 5,251 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-023674 · doc4.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,251 Underlying: Common Stock · 5,251 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3 · derivative.exercise_date: The restricted stock units awarded on March 27, 2019, vest in three equal installments on March 27, 2020, March 27, 2021, and March 27, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F3 · derivative.expiration_date: The restricted stock units awarded on March 27, 2019, vest in three equal installments on March 27, 2020, March 27, 2021, and March 27, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| March 27, 2021 Filed Mar 30, 2021 20:45 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 5,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023674 · doc4.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of restricted stock units awarded on March 27, 2019. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:41 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 342,300 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000037 · wf-form4_161650328116144.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,300 Underlying: Common Stock · 342,300 shares Expires 2031-03-19 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:41 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 109,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000037 · wf-form4_161650328116144.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,365 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| March 19, 2021 Filed Mar 31, 2021 16:37 UTC Amendment | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 342,300 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000048 · wf-form4a_161720862617060.xml · derivative · entry 3 Jain Rita · CIK 0001707797 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,300 Underlying: Common Stock · 342,300 shares Expires 2031-03-19 F4 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| March 19, 2021 Filed Mar 31, 2021 16:37 UTC Amendment | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 11,765 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000048 · wf-form4a_161720862617060.xml · nonDerivative · entry 2 Jain Rita · CIK 0001707797 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,365 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F3 · shares: The original Form 4, filed on March 23, 2021, is being amended by this Form 4 amendment solely to correct an administrative error related to the disclosure of the vesting schedule for 11,765 RSUs. These RSUs vest in their entirety six months after the date of grant on September 19, 2021, subject to the Reporting Person providing continuous service to the Issuer as of such date. Read SEC document |
| March 19, 2021 Filed Mar 31, 2021 16:37 UTC Amendment | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 97,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000048 · wf-form4a_161720862617060.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,600 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 22, 2021 Filed Jan 25, 2021 21:39 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 220,000 | $0.00 Strike: $42.19 | $0.00 |
DisclosureSEC source: 0001764013-21-000006 · wf-form4_161161076317026.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2031-01-22 F3 · derivative.exercise_date: Shares underlying the option vest over four years, with 25% of the shares underlying the option vesting on January 11, 2022, and the remainder of shares underlying the option vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 22, 2021 Filed Jan 25, 2021 21:39 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000006 · wf-form4_161161076317026.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on January 11, 2022 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:45 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantRestricted Stock Units · Derivative | 4,660 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032206 · doc4.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,660 Underlying: Common Stock · 4,660 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F4 · derivative.exercise_date: The restricted stock units awarded on May 21, 2020, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F4 · derivative.expiration_date: The restricted stock units awarded on May 21, 2020, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:45 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy) · Derivative | 2,888 | Not disclosed Strike: $59.73 | Not disclosed |
DisclosureSEC source: 0001209191-20-032206 · doc4.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,888 Underlying: Common Stock · 2,888 shares Expires 2030-05-21 F2 · price: Not applicable. F1 · derivative.exercise_date: The option granted on May 21, 2020, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 19:10 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionRestricted Stock Units · Derivative | 5,251 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-021909 · doc4.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,502 Underlying: Common Stock · 5,251 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F3 · derivative.exercise_date: The restricted stock units awarded on March 27, 2019, vest in three equal installments on March 27, 2020, March 27, 2021, and March 27, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F3 · derivative.expiration_date: The restricted stock units awarded on March 27, 2019, vest in three equal installments on March 27, 2020, March 27, 2021, and March 27, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| March 27, 2020 Filed Mar 31, 2020 19:10 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Exercise / conversionCommon Stock | 5,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-021909 · doc4.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares were acquired upon vesting of restricted stock units awarded on March 27, 2019. Read SEC document |
| May 23, 2019 Filed May 23, 2019 20:53 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantStock Option (right to buy) · Derivative | 12,287 | Not disclosed Strike: $11.60 | Not disclosed |
DisclosureSEC source: 0001209191-19-032537 · doc4.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,287 Underlying: Common Stock · 12,287 shares Expires 2029-05-23 F3 · price: Not applicable. F2 · derivative.exercise_date: The option granted on May 23, 2019, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Read SEC document |
| May 23, 2019 Filed May 23, 2019 20:53 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantCommon Stock | 7,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032537 · doc4.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,724 F1 · shares: The restricted stock awarded on May 23, 2019, vests on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company on such date. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 20:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Disposition to issuerCommon Stock | 4,409 | $7.70 | $33,949.30 |
DisclosureSEC source: 0000899243-19-010591 · doc4.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,332 F1 · shares: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 20:02 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | GrantRestricted Stock Units · Derivative | 15,753 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021879 · doc4.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,753 Underlying: Common Stock · 15,753 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CCXI common stock. F2 · derivative.exercise_date: The restricted stock units awarded on March 27, 2019, vest in three equal installments on March 27, 2020, March 27, 2021, and March 27, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. F2 · derivative.expiration_date: The restricted stock units awarded on March 27, 2019, vest in three equal installments on March 27, 2020, March 27, 2021, and March 27, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 21:07 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 115,000 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001562180-19-001679 · primarydocument.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2029-02-28 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 21:07 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-001679 · primarydocument.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,741 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 13:17 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Tax withholdingCommon Stock | 8,659 | $8.94 | $77,411.46 |
DisclosureSEC source: 0000899243-18-030796 · doc4.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,741 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 41,800 | $0.00 Strike: $14.30 | $0.00 |
DisclosureSEC source: 0001562180-18-001388 · primarydocument.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,800 Underlying: Common Stock · 41,800 shares Expires 2028-02-28 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan. 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 29,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001388 · primarydocument.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,400 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0001562180-17-002141 · primarydocument.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: This option will vest as to 25% of the shares of common stock subject to the award on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.